Department of Physiology and Pharmacology, College of Medicine, Chang Gung University, Taoyuan 33302, Taiwan.
Department of Neurology, Chang Gung Memorial Hospital, Taoyuan 33305, Taiwan.
Molecules. 2019 Sep 19;24(18):3407. doi: 10.3390/molecules24183407.
In thrombolytic therapy, plasminogen activators (PAs) are still the only group of drug approved to induce thrombolysis, and therefore, critical for treatment of arterial thromboembolism, such as stroke, in the acute phase. Functionalized nanocomposites have attracted great attention in achieving target thrombolysis due to favorable characteristics associated with the size, surface properties and targeting effects. Many PA-conjugated nanocomposites have been prepared and characterized, and some of them has been demonstrated with therapeutic efficacy in animal models. To facilitate future translation, this paper reviews recent progress of this area, especially focus on how to achieve reproducible thrombolysis efficacy .
在溶栓治疗中，纤溶酶原激活剂（PAs）仍然是唯一被批准用于诱导溶栓的药物类别，因此对于治疗急性动脉血栓栓塞症（如中风）至关重要。功能化纳米复合材料由于与尺寸、表面特性和靶向作用相关的有利特性，在实现靶向溶栓方面引起了极大的关注。已经制备和表征了许多与 PA 缀合的纳米复合材料，其中一些已在动物模型中显示出治疗效果。为了便于未来的转化，本文综述了该领域的最新进展，特别是如何实现可重复的溶栓效果。
